266 related articles for article (PubMed ID: 17425704)
1. The discovery of a new drug class for the acute treatment of migraine.
Humphrey PP
Headache; 2007 Apr; 47 Suppl 1():S10-9. PubMed ID: 17425704
[TBL] [Abstract][Full Text] [Related]
2. The discovery and development of the triptans, a major therapeutic breakthrough.
Humphrey PP
Headache; 2008 May; 48(5):685-7. PubMed ID: 18471110
[TBL] [Abstract][Full Text] [Related]
3. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
4. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
5. [Triptans--pivotal event in migraine treatment].
Lusić I; Bilić I
Acta Med Croatica; 2008 May; 62(2):173-8. PubMed ID: 18710081
[TBL] [Abstract][Full Text] [Related]
6. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
Peroutka SJ
Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
[TBL] [Abstract][Full Text] [Related]
7. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
8. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
9. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Elkind AH; MacGregor EA
Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan.
Peterlin BL; Rapoport AM
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):899-911. PubMed ID: 18028032
[TBL] [Abstract][Full Text] [Related]
11. The triptans.
Bigal ME; Krymchantowski AV; Hargreaves R
Expert Rev Neurother; 2009 May; 9(5):649-59. PubMed ID: 19402776
[TBL] [Abstract][Full Text] [Related]
12. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats.
Reuter U; Salomone S; Ickenstein GW; Waeber C
Cephalalgia; 2004 May; 24(5):398-407. PubMed ID: 15096229
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
14. Early treatment in migraine: how strong is the current evidence?
Gendolla A
Cephalalgia; 2008 Sep; 28 Suppl 2():28-35. PubMed ID: 18715330
[TBL] [Abstract][Full Text] [Related]
15. [Triptans in migraine--here and now (15 years after they were implemented in therapy)].
Prusiński A; Rozniecki JJ
Neurol Neurochir Pol; 2005; 39(4 Suppl 1):S68-77. PubMed ID: 16419574
[TBL] [Abstract][Full Text] [Related]
16. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?
Shields KG; Goadsby PJ
Neurobiol Dis; 2006 Sep; 23(3):491-501. PubMed ID: 16875831
[TBL] [Abstract][Full Text] [Related]
17. Can we develop neurally acting drugs for the treatment of migraine?
Goadsby PJ
Nat Rev Drug Discov; 2005 Sep; 4(9):741-50. PubMed ID: 16121129
[TBL] [Abstract][Full Text] [Related]
18. Serotonin receptors and the acute attack of migraine.
Goadsby PJ
Clin Neurosci; 1998; 5(1):18-23. PubMed ID: 9523053
[TBL] [Abstract][Full Text] [Related]
19. New migraine and pain research.
Hargreaves R
Headache; 2007 Apr; 47 Suppl 1():S26-43. PubMed ID: 17425708
[TBL] [Abstract][Full Text] [Related]
20. Ten years of rizatriptan: from development to clinical science and future directions.
Hargreaves RJ; Lines CR; Rapoport AM; Ho TW; Sheftell FD
Headache; 2009 Feb; 49 Suppl 1():S3-20. PubMed ID: 19161563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
